Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out – Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology

Published

on

essential-thrombocythemia-market-to-witness-upsurge-in-growth-by-2032,-predicts-delveinsight-|-key-companies-to-look-out-–-imago-biosciences,-incyte,-karyopharm,-novartis,-pharmaessentia,-celgene,-kartos,-sierra-oncology

The key drivers for the essential thrombocythemia market is increase in prevalence, reach of bone marrow biopsy, and updated diagnosed criteria. These factors along with the expected launch of emerging therapies will boost the essential thrombocythemia market in the forecasted period.
LAS VEGAS, Aug. 30, 2023 /PRNewswire/ — DelveInsight’s Essential Thrombocythemia Market Insights report includes a comprehensive understanding of current treatment practices, essential thrombocythemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Essential Thrombocythemia Market Report
As per DelveInsight analysis, the essential thrombocythemia market is expected to grow positively at a significant CAGR during the study period (2019–2032).As per DelveInsight analysts, total prevalent population of essential thrombocythemia in the 7MM was 240K in 2020. Estimates observed that the age-group 60-80 years accounted for highest cases of essential thrombocythemia in the United States.Leading essential thrombocythemia companies such as Imago BioSciences, Inc, Incyte Corporation, Karyopharm Therapeutics Inc, Novartis, PharmaEssentia, CTI BioPharma, Celgene, NS Pharma, Inc., Kartos Therapeutics, Inc., Sierra Oncology LLC, GlaxoSmithKline, Incyte Corporation, and others are developing novel essential thrombocythemia drugs that can be available in the essential thrombocythemia market in the coming years.Some key therapies for essential thrombocythemia treatment include IMG-7289, Ruxolitinib, Selinexor, Reparixin, Ropeginterferon alfa-2b, Pacritinib, FEDRATINIB, NS-018, KRT-232, Momelotinib, MMB, INCB000928, Bomedemstat, and others.Discover which therapies are expected to grab the major essential thrombocythemia market share @ Essential Thrombocythemia Market Report
Essential Thrombocythemia Overview
Essential thrombocythemia is a rare chronic disorder of the bone marrow characterized by an excessive production of platelets, the blood cells responsible for clotting. While the exact cause of essential thrombocythemia is not fully understood, it is often linked to genetic mutations affecting the bone marrow cells responsible for platelet production. These mutations lead to the overproduction of platelets, which can result in an increased risk of abnormal blood clotting and bleeding.
Symptoms of essential thrombocythemia can vary and may include unusual bleeding or bruising, headaches, dizziness, and in some cases, tiny red spots on the skin known as petechiae. Some individuals with essential thrombocythemia may also experience enlarged spleens, which can cause discomfort or a feeling of fullness in the abdomen.
Diagnosing essential thrombocythemia involves a combination of clinical evaluation, blood tests, and bone marrow examination. Blood tests help assess platelet counts, as well as the presence of other blood cell abnormalities. Genetic testing may also be conducted to identify mutations associated with the disorder. A bone marrow biopsy might be performed to confirm the diagnosis and to rule out other potential causes of elevated platelet levels.
Essential Thrombocythemia Epidemiology Segmentation
The essential thrombocythemia epidemiology section provides insights into the historical and current essential thrombocythemia patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. 
The essential thrombocythemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Essential Thrombocythemia Prevalent CasesPrevalence of Essential Thrombocythemia Based on SymptomsEssential Thrombocythemia Gender-specific PrevalenceEssential Thrombocythemia Age-specific PrevalencePrevalence of Essential Thrombocythemia Cases Based on RiskEssential Thrombocythemia Gene Mutation-specific PrevalenceEssential Thrombocythemia Treatment Market 
The primary goal of essential thrombocythemia treatment is to manage and prevent complications associated with excessive platelet levels, which can lead to blood clotting, bleeding, or enlargement of the spleen. Essential thrombocythemia treatment approaches may vary based on factors such as age, overall health, and risk of complications. Common strategies include platelet-lowering medications like hydroxyurea and anagrelide, which help regulate platelet production by targeting the abnormal cells in the bone marrow. Additionally, aspirin may also be prescribed to reduce the risk of clotting by inhibiting platelet aggregation.
In more severe cases or when other treatments are ineffective, procedures like plateletpheresis, a process where platelets are removed from the blood, might be considered to rapidly lower platelet counts. Rarely, bone marrow transplantation might be considered as a more definitive treatment option, especially in younger patients with severe and resistant forms of essential thrombocythemia. Regular medical monitoring is essential to adjust treatments, assess the progression of the disease, and prevent potential complications. This underscores the importance of personalized and comprehensive care for individuals with essential thrombocythemia, as its management often requires a multidisciplinary approach involving hematologists, oncologists, and other medical specialists. With the right treatment regimen and careful monitoring, many individuals with essential thrombocythemia can effectively manage their condition and lead full and productive lives.
To know more about essential thrombocythemia treatment, visit @ Essential Thrombocythemia Treatment Drugs 
Key Essential Thrombocythemia Therapies and Companies
IMG-7289: Imago BioSciences, IncRuxolitinib: Incyte CorporationSelinexor: Karyopharm Therapeutics IncReparixin: NovartisRopeginterferon alfa-2b: PharmaEssentiaPacritinib: CTI BioPharmaFEDRATINIB: CelgeneNS-018: NS Pharma, Inc.KRT-232: Kartos Therapeutics, Inc.Momelotinib: Sierra Oncology LLCMMB: GlaxoSmithKlineINCB000928: Incyte CorporationBomedemstat: Imago BioSciencesLearn more about the FDA-approved drugs for essential thrombocythemia @ Drugs for Essential Thrombocythemia Treatment 
Essential Thrombocythemia Market Dynamics
The essential thrombocythemia market dynamics are driven by a multifaceted range of factors. Advances in medical research and technology, particularly in genetic profiling and molecular diagnostics, are enabling more accurate and early detection of essential thrombocythemia cases. This, in turn, leads to an expanding patient pool as awareness and diagnosis rates improve. 
Additionally, the growing emphasis on personalized medicine is pushing pharmaceutical companies to develop innovative therapies that target the underlying mechanisms of essential thrombocythemia with greater precision. Collaborative efforts between academia, industry, and patient advocacy groups also contribute to knowledge sharing and therapeutic advancements.
However, several barriers and challenges impact the essential thrombocythemia market dynamics. One of the major barriers is the rarity of the condition, making it challenging to conduct large-scale clinical trials and gather sufficient data for robust research. Moreover, the high costs associated with developing and manufacturing specialized treatments for rare diseases can limit accessibility for patients. 
Regulatory hurdles and the need for stringent safety and efficacy assessments further add complexity to the development and approval process of new therapies. Reimbursement issues, particularly in healthcare systems with limited coverage for novel treatments, can also hinder patient access to cutting-edge therapies. Balancing the drive for innovation with addressing these barriers remains a pivotal challenge in shaping the essential thrombocythemia market dynamics.
Report Metrics
Details
Study Period
2019–2032
Coverage
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Essential Thrombocythemia Companies
Imago BioSciences, Inc, Incyte Corporation, Karyopharm Therapeutics Inc, Novartis, PharmaEssentia, CTI BioPharma, Celgene, NS Pharma, Inc., Kartos Therapeutics, Inc., Sierra Oncology LLC, GlaxoSmithKline, Incyte Corporation, and others
Key Essential Thrombocythemia Therapies
IMG-7289, Ruxolitinib, Selinexor, Reparixin, Ropeginterferon alfa-2b, Pacritinib, FEDRATINIB, NS-018, KRT-232, Momelotinib, MMB, INCB000928, Bomedemstat, and others
 
Scope of the Essential Thrombocythemia Market Report
Therapeutic Assessment: Essential Thrombocythemia current marketed and emerging therapiesEssential Thrombocythemia Market Dynamics: Conjoint Analysis of Emerging Essential Thrombocythemia DrugsCompetitive Intelligence Analysis: SWOT analysis and Market entry strategiesUnmet Needs, KOL’s views, Analyst’s views, Essential Thrombocythemia Market Access and ReimbursementDiscover more about essential thrombocythemia drugs in development @ Essential Thrombocythemia Clinical Trials
Table of Contents
1.
Essential Thrombocythemia Market Key Insights
2.
Essential Thrombocythemia Market Report Introduction
3.
Essential Thrombocythemia Market Overview at a Glance
4.
Essential Thrombocythemia Market Executive Summary
5.
Disease Background and Overview
6.
Essential Thrombocythemia Treatment and Management
7.
Essential Thrombocythemia Epidemiology and Patient Population
8.
Patient Journey
9.
Essential Thrombocythemia Marketed Drugs
10.
Essential Thrombocythemia Emerging Drugs
11.
Seven Major Essential Thrombocythemia Market Analysis
12.
Essential Thrombocythemia Market Outlook
13.
Potential of Current and Emerging Therapies
14.
KOL Views
15.
Unmet Needs
16.
SWOT Analysis
17.
Appendix
18.
DelveInsight Capabilities
19.
Disclaimer
20.
About DelveInsight
 
Related Reports
Essential Thrombocythemia Pipeline
Essential Thrombocythemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key essential thrombocythemia companies, including PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals, among others.
Thalassemia Market
Thalassemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key thalassemia companies, including Forma therapeutics, Ionis Pharmaceuticals, Gamida-Cell, Silence Therapeutics, among others.
Beta Thalassemia Market
Beta Thalassemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key beta thalassemia companies, including Novartis, Merck, Bristol Myers Squibb, Chiesi Farmaceutici S.p.A, Bluebird Bio, among others.
Alpha Thalassemia Market 
Alpha Thalassemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key alpha thalassemia companies, including CRISPR Therapeutics, Agios Pharmaceuticals, DisperSol Technologies, Celgene, EmeraMed, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur [email protected]  +1(919)321-6187 www.delveinsight.com 
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/essential-thrombocythemia-market-to-witness-upsurge-in-growth-by-2032-predicts-delveinsight–key-companies-to-look-out—imago-biosciences-incyte-karyopharm-novartis-pharmaessentia-celgene-kartos-sierra-oncology-301912045.html

Continue Reading

Artificial Intelligence

Unlock an Exclusive Olympic Experience: Celebrating Live4Well’s Sold-Out Genesis NFT

Published

on

unlock-an-exclusive-olympic-experience:-celebrating-live4well’s-sold-out-genesis-nft

HONG KONG, May 25, 2024 /PRNewswire/ — The buzz surrounding Live4Well’s successful Genesis NFT membership launch on May 23 has captivated both traditional and web3 communities. Combining the power of AI technology and decentralized physical infrastructure (DePin) concept, Live4Well has infused new life into the NFT market. The overwhelming response to their first NFT sales, showcases the project’s immense potential. Renowned web3 community leaders from Azuki, Bored Ape, Pudgy Penguins, WELL3, etc have joined forces with Live4Well, propelling the Genesis NFT membership collection to its resounding success.

Live4Well aims to transform the wellness industry by creating a reward-based infrastructure that connects global fitness data, enhances their AI database, and drives the development of sports and wellness. Backed by a multi-billion family office, which recently invested $20 million in Live4Well, the project has gained support in both web3 and traditional spaces. The team believes that every drop of sweat and effort toward better health should be rewarded, fostering motivation and integrating exercise into daily lives for enhanced well-being.
Live4Well’s announcement of an Olympic-themed raffle for Genesis NFT holders reflects their commitment to connecting wellness between Web2 and Web3 platforms. This testament to Live4Well’s demand and innovative vision solidifies their position as a promising leader in the industry. Their integration of the Olympic signifies their determination to inspire a global audience, leveraging blockchain technology to create an immersive ecosystem that revolutionizes how individuals engage with fitness on a daily basis for better health. Live4Well’s dedication to bridging the gap between traditional practices and the digital landscape sets them apart as pioneers in promoting well-being on a global scale.
What is Genesis NFT membership?
The Genesis NFT unlocks a multitude of benefits for holders, including the opportunity to cash out their sportive income and access a range of exclusive physical products and services. In addition to future airdrops and angel round whitelist privileges, Genesis holders will receive VIP tailor-made product packs from an innovative German sportswear company, elevating their exercise performance to new heights. With over 400 million sweat points farmed by their users, they are eager to redeem through the Genesis NFT membership. These enticing incentives explain why there was a widespread eagerness to participate in this thrilling event.
Unlike typical projects that raise funds before launching products or services, Live4Well has already released its AI-powered app, amassing over 250,000 users as a community base actively engaging in daily exercise. This early success has fostered a promising community within the wellness industry, as users trust Live4Well’s roadmap and collaborative ventures. The growing traction from both ordinary individuals and web3 enthusiasts has intensified the demand for redeeming and cashing out sweat points, the project’s exercise-based rewards. Obtaining the Genesis NFT membership is now seen as an essential step for accessing the highest tier of benefits and cashing out sportive income.
What’s next for Live4Well?
Following the Genesis sales, Live4Well’s team will shift their focus to the upcoming token generation event (TGE) and a series of farming events. They also have exciting plans for partnerships and other collaborations in the global wellness and fitness industries. If you missed the initial launch, be sure to stay updated on Live4Well’s journey and join this extraordinary revolution.
Photo – https://mma.prnewswire.com/media/2421983/image.jpg
Photo – https://mma.prnewswire.com/media/2421640/Live4Well.jpg
Logo – https://mma.prnewswire.com/media/2421641/4725441/Live4Well.jpg
 
 

View original content:https://www.prnewswire.co.uk/news-releases/unlock-an-exclusive-olympic-experience-celebrating-live4wells-sold-out-genesis-nft-302155644.html

Continue Reading

Artificial Intelligence

Overseas Expansion Strategy of K-OTT Introduced in France, KOCCA holds the ‘2024 Korea-France Content Forum’

Published

on

overseas-expansion-strategy-of-k-ott-introduced-in-france,-kocca-holds-the-‘2024-korea-france-content-forum’

– The ‘Korea-France Content Forum’ held to establish the Foundation for K-OTT’s oversea expansion
PARIS, May 24, 2024 /PRNewswire/ — The Ministry of Culture, Sports and Tourism (Minister Yu In-chon) and the Korea Creative Content Agency (President, Jo Hyun-rae, hereafter KOCCA) held the ‘2024 Korea-France Content Forum’ on May 24th during the Korea Expo in Paris, France.

The ‘2024 Korea-France Content Forum’ featured a keynote session (K-OTT’s Strategies in Global market) presenting K-OTT’s strategies for international expansion and a roundtable session (Strategies in the Era of Streaming) discussing the growth of OTT platforms and collaborative approaches with production companies.
The forum featured participation from various industry leaders including Kun hee Park (CEO, Wavve Americas), Sangjin Lee (Head of content IP Business, LG U+), Seung ae Sohn (Executive Director, Showbox), Ji ae Sohn (Ambassador for Cultural Cooperation), Moonju Kim (General Director, France Business Center, KOCCA), Isabelle Degeorges (President, Gaumont Television France) which produced the French Netflix original series, participated.
Strategy announcement by Wavve Americas (KOCAWA), the first K-OTT’s launched in Europe
During the Keynote Session, Park Kun Hee – CEO of Wavve Americas, the first domestic OTT Platform to launch services in Europe, Took the stage to discuss the international expansion strategy of KOCOWA, which started offering services in 39 countries including Europe since April of this year. Following this, Lee Sangjin, Head of Content IP Business of LG U+, presented the expansion strategy of LG U+ Mobile TV, encompassing diverse original content.
During the round-table session, participants shared thoughts and solutions regarding the survival strategies of local OTT platforms and production companies amidst the rapid waves of change brought about by the emergence of global OTT platforms.
In particular, through this forum, we were able to observe the proactive implementation of IP protection policies by local production companies in France, aimed at sustainable content creation. Isabelle Degeorges, CEO of Gaumont Television France, noted, “With the introduction of the European Audiovisual Media Services Directive (AVMSD), platforms and production companies can share IPs three years after supplying the content.” Kim Moon-joo, Director of the Korea Creative Content Agency’s France Business Center, participated as a panelist, introducing policies aimed at enhancing the competitiveness of K-OTT and fostering collaboration with production companies.
Park Kun Hee, CEO of Wavve Americas, who participated in the event, stated, “It was a meaningful opportunity to introduce our platform locally in Europe in line with KOCOWA’s expansion into the region”. Additionally, Kyoungbon Koo, Director Broadcasting & Video Content Division at KOCCA commented, “It was a meaningful occasion to not only introduce K-OTT’s strategies to Europe but also to exchange ideas on collaboration between Korea and France. We will continue to focus on activating various forms of collaboration with major international partners in the future”.
KOCCA supports the overseas expansion of excellent domestic OTT content and platforms through the newly established Local OTT Specialized Support Program this year. This initiative aims to enhance the competitiveness of domestic OTT platforms and content by adapting to the changing industrial environment.
Photo – https://mma.prnewswire.com/media/2421769/Korea_France_Content_Forum_Photo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/overseas-expansion-strategy-of-k-ott-introduced-in-france-kocca-holds-the-2024-korea-france-content-forum-302155362.html

Continue Reading

Artificial Intelligence

IoT Node and Gateway Market worth $604.7 billion by 2029 – Exclusive Report by MarketsandMarkets™

Published

on

iot-node-and-gateway-market-worth-$604.7-billion-by-2029-–-exclusive-report-by-marketsandmarkets™

CHICAGO, May 24, 2024 /PRNewswire/ — The IoT Node and Gateway market is projected to grow from USD 424.6 billion in 2024 and is estimated to reach USD 604.7 billion by 2029; it is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.3% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth of the IoT Node and Gateway market is driven by the Provision of increased IP address space through IPv6, Emergence of 5G technology, and Increasing need for data centers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=248007097
Browse in-depth TOC on “IoT Node and Gateway Market”
410 – Tables70 – Figures390 – Pages
IoT Node and Gateway Market Report Scope:
Report Coverage
Details
Market Revenue in 2024
$ 424.6 billion
Estimated Value by 2029
$ 604.7 billion
Growth Rate
Poised to grow at a CAGR of 7.3%
Market Size Available for
2020–2029
Forecast Period
2024–2029
Forecast Units
Value (USD Million/Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
By Hardware, End-use Application and Region
Geographies Covered
North America, Europe, Asia Pacific, and Rest of World
Key Market Challenge
Requirement for wireless spectrum and licensed spectrum
Key Market Opportunities
Accelerated IoT adoption in healthcare sector
Key Market Drivers
Rising use of wireless smart sensors and networks
By Hardware, the Logic Devices are projected to grow at a high CAGR of IoT Node and Gateway market during the forecast period.
Logic devices can adapt to changing requirements even after deployment. As new features or functionalities are needed, the logic within the device can be reprogrammed to accommodate these changes, extending the useful life of the product and reducing the need for hardware revisions. The integration of FPGA technology into IoT devices further enhances these advantages. The integration of FPGAs into IoT nodes and gateways empowers manufacturers to develop highly optimized, customizable, and scalable solutions that meet the diverse needs of IoT applications. Tesla’s Full Self-Driving (FSD) computer utilizes FPGAs to handle complex neural network computations for autonomous driving algorithms. This allows them to potentially improve their FSD capabilities through software updates that reconfigure the logic within the FPGAs.
BFSI segment in IoT Node and Gateway Market is projected to grow at a highest CAGR during the forecast period.
BFSI sector can use IoT technology to provide more convenient solutions for customers. IoT can be used to perform data collection in real time and for instant communication between devices. For instance, it can facilitate cashless payments using an RFID scanner to identify products in the shopping cart and mobile wallet. The adoption of mobile point of sale (mPOS) systems and kiosks is fundamentally reshaping the landscape of the BFSI market. mPOS facilitates transactions anytime, anywhere, benefiting unbanked populations and enabling temporary service points for events. Kiosks offer convenient banking functionalities, reducing wait times and freeing up staff for complex inquiries. These technologies drive cost savings by requiring less investment and automating routine tasks, allowing resources to be reallocated strategically. They provide rich data for personalized services, fraud detection, and operational optimization. mPOS systems and kiosks promote financial inclusion by extending services to remote areas, fostering economic activity and well-being.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=248007097
North America accounts for the largest share in IoT Node and Gateway Industry.
The North American IoT market is poised to grow, driven by government efforts to transition cities into smart urban centers. The growing need for sophisticated IoT solutions, fueled by the widespread availability of high-speed data, will further propel market expansion in this region. Furthermore, North America’s dynamic IoT node and gateway ecosystem features established players like Intel Corporation (US), Texas Instruments Incorporated (US), Dell (US), and Cisco Systems (US), driving competition, innovation, and affordability. Increasing research and development at industry levels is broadening the application areas of IoT in various industries, such as retail, consumer electronics, automotive and transportation, and healthcare, especially in the US. The increased demand for effective solutions and focus on early, accurate, and fast diagnosis of diseases has led to huge investments in technological developments in the healthcare sector.
Key Players
Key companies operating in the IoT Node and Gateway companies are Intel Corporation (US), Qualcomm Technologies, Inc. (US), Texas Instruments Incorporated (US), STMicroelectronics (Switzerland), Microchip Technology Inc. (US), Huawei Technologies Co., Ltd. (China), NXP Semiconductors N.V. (Netherlands), Cisco Systems, Inc. (US), Hewlett Packard Enterprise Development LP (US), TE Connectivity Ltd (Switzerland), Advantech Co., Ltd. (Taiwan), Dell Technologies (US), among others.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=248007097
Browse Adjacent Market: Semiconductor and Electronics Market Research Reports &Consulting
Related Reports: 
IoT Technology Market by Node Component (Sensor, Memory Device, Connectivity IC, Processor, Logic Devices), Software Solution (Remote Monitoring, Data Management), Platform, Service, End-use Application, Geography – Global Forecast to 2029
Industrial IoT Market Size, Share & Industry Growth Analysis Report by Device & Technology, Connectivity Type, Software, Vertical (Manufacturing, Energy, Oil & Gas, Healthcare, Retail, Transportation, Metals & Mining, Agriculture), and Geography – Global Growth Driver and Industry Forecast to 2026
Internet of Robotic Things Market (IoRT) by Component (Sensor, Power, Control), Service (Professional, Managed), Platform (Device, Application, Network), Software (Analytics, Data, Security, Monitoring, Bandwidth), Application – Global Forecast to 2022
MulteFire Market by Device (Small Cells, Switches, Controllers), Application (Industrial Manufacturing, Commercial, Transportation, Public Venues, Healthcare, Oil & Gas and Mining, Power Generation, Hospitality), and Geography – Global forecast 2025
Smart Robots Market Size, Share by Component (Sensors, Actuators, Control Systems), Type, Operating Environment, Mobility, Application (Domestic, Field/Agricultural, Public Relations, Industrial), and Region – Global Forecast to 2025
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact: Mr. Aashish MehraMarketsandMarkets™ INC. 630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Our Web Site: https://www.marketsandmarkets.com/Research Insight: https://www.marketsandmarkets.com/ResearchInsight/iot-gateway-market.aspContent Source: https://www.marketsandmarkets.com/PressReleases/iot-gateway.asp
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/iot-node-and-gateway-market-worth-604-7-billion-by-2029—exclusive-report-by-marketsandmarkets-302155034.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending